Published in Cancer Res on November 03, 2015
Patient-derived xenografts as in vivo models for research in urological malignancies. Nat Rev Urol (2017) 0.75
Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer. Clin Med Insights Oncol (2016) 0.75
MET expression during prostate cancer progression. Oncotarget (2016) 0.75
Fluid shear stress activates YAP1 to promote cancer cell motility. Nat Commun (2017) 0.75
Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med (2013) 13.90
Interactions between cancer stem cells and their niche govern metastatic colonization. Nature (2011) 6.94
Ligand binding to integrins. J Biol Chem (2000) 4.94
Integrin ligands at a glance. J Cell Sci (2006) 4.76
Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med (2011) 4.25
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol (2012) 3.92
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol (2014) 3.40
Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res (2008) 3.11
Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res (2006) 2.86
The de-adhesive activity of matricellular proteins: is intermediate cell adhesion an adaptive state? J Clin Invest (2001) 2.55
SPARC, a secreted protein associated with cellular proliferation, inhibits cell spreading in vitro and exhibits Ca+2-dependent binding to the extracellular matrix. J Cell Biol (1989) 2.10
Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells. Cancer Res (2009) 2.04
Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst (2011) 1.98
Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate (1999) 1.92
Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest (2008) 1.87
The alpha 6 beta 1 and alpha 6 beta 4 integrins in human prostate cancer progression. Cancer Metastasis Rev (1995) 1.84
Talin1 promotes tumor invasion and metastasis via focal adhesion signaling and anoikis resistance. Cancer Res (2010) 1.74
Cadherin-11 promotes the metastasis of prostate cancer cells to bone. Mol Cancer Res (2008) 1.67
Integrins in prostate cancer progression. Endocr Relat Cancer (2008) 1.56
Integrins and prostate cancer metastases. Cancer Metastasis Rev (2001) 1.51
Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. J Clin Oncol (2012) 1.48
Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship. Sci Transl Med (2014) 1.34
A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clin Cancer Res (2013) 1.33
Tumor-stroma co-evolution in prostate cancer progression and metastasis. Semin Cell Dev Biol (2009) 1.26
BMP4 promotes prostate tumor growth in bone through osteogenesis. Cancer Res (2011) 1.23
Revisiting the matricellular concept. Matrix Biol (2014) 1.14
β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma. Cancer Res (2013) 1.12
Mechanism-based cancer therapy: resistance to therapy, therapy for resistance. Oncogene (2014) 1.10
The laminin binding integrin alpha6beta1 in prostate cancer perineural invasion. J Cell Physiol (2010) 1.06
β1 integrin: Critical path to antiangiogenic therapy resistance and beyond. Cancer Res (2013) 1.03
Targeting constitutively activated β1 integrins inhibits prostate cancer metastasis. Mol Cancer Res (2013) 1.01
Talin1 phosphorylation activates β1 integrins: a novel mechanism to promote prostate cancer bone metastasis. Oncogene (2014) 1.00
Definition of molecular determinants of prostate cancer cell bone extravasation. Cancer Res (2012) 0.98
Expression of the extracellular domain of OB-cadherin as an Fc fusion protein using bicistronic retroviral expression vector. Protein Expr Purif (2008) 0.96
Binding of αvβ1 and αvβ6 integrins to tenascin-C induces epithelial-mesenchymal transition-like change of breast cancer cells. Oncogenesis (2013) 0.95
High-throughput tyrosine kinase activity profiling identifies FAK as a candidate therapeutic target in Ewing sarcoma. Cancer Res (2013) 0.90
Emerging roles of focal adhesion kinase in cancer. Biomed Res Int (2015) 0.90
Expression of recombinant MDA-BF-1 with a kinase recognition site and a 7-histidine tag for receptor binding and purification. Protein Expr Purif (2005) 0.89
The counteradhesive protein SPARC regulates an endothelial paracellular pathway through protein tyrosine phosphorylation. Biochem Biophys Res Commun (1998) 0.89
Emerging therapies in castration resistant prostate cancer. Can J Urol (2014) 0.88
Secretome analysis of an osteogenic prostate tumor identifies complex signaling networks mediating cross-talk of cancer and stromal cells within the tumor microenvironment. Mol Cell Proteomics (2014) 0.86
RSK promotes prostate cancer progression in bone through ING3, CKAP2, and PTK6-mediated cell survival. Mol Cancer Res (2014) 0.85
Benchtop isolation and characterization of functional exosomes by sequential filtration. J Chromatogr A (2014) 0.85
Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer. Clin Cancer Res (2015) 0.85
Safety, tolerability, and pharmacokinetics of the novel αv-integrin antibody EMD 525797 (DI17E6) in healthy subjects after ascending single intravenous doses. Invest New Drugs (2013) 0.78
Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers. Clin Cancer Res (2015) 0.86
Inhibition of cell adhesion by a cadherin-11 antibody thwarts bone metastasis. Mol Cancer Res (2013) 0.86
RSK promotes prostate cancer progression in bone through ING3, CKAP2, and PTK6-mediated cell survival. Mol Cancer Res (2014) 0.85
Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramifications. Clin Cancer Res (2014) 0.79
XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A. Clin Cancer Res (2015) 0.78
An unusual cause of left lower quadrant abdominal pain. Gastroenterology (2019) 0.75
Modeling of Patient Derived Xenografts in Colorectal Cancer. Mol Cancer Ther (2017) 0.75